Literature DB >> 16520263

Outpatient continuous parenteral inotropic therapy as bridge to transplantation in children with advanced heart failure.

Jack F Price1, Jeffrey A Towbin, William J Dreyer, Brady S Moffett, Naomi J Kertesz, Sarah K Clunie, Susan W Denfield.   

Abstract

BACKGROUND: Advanced heart failure in children is associated with high morbidity and mortality and is often refractory to standard medical therapy. The purpose of this study was to review our institutional experience with the use of outpatient parenteral inotropic therapy (PIT) for advanced chronic heart failure in children. METHODS AND
RESULTS: We reviewed the medical records of all patients treated with PIT as outpatients. Seven patients received outpatient PIT from 2/99 to 1/05 (mean age was 14.6 years +/- 3.7). Median duration of therapy was 10 weeks (range 4-84 weeks). The mean number of emergency department visits per patient was greater before starting PIT than after starting PIT (2.3 +/- 1.8 versus 1.1 +/- 2.2, P < .05). The mean number of hospital admissions from exacerbation of heart failure symptoms decreased after starting PIT (2.1 +/- 1.3 versus 0.6 +/- 0.8, P < .05). Mean EF% in patients with systolic dysfunction improved while on therapy (30 +/- 14% before versus 39 +/- 16% after, P < .05). There was 1 death and 5 complications in 2 patients. Six patients were successfully bridged to transplantation.
CONCLUSION: Outpatient continuous parenteral inotropic therapy may serve as a successful bridge to cardiac transplantation in selected pediatric outpatients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16520263     DOI: 10.1016/j.cardfail.2005.11.001

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  20 in total

Review 1.  A multidimensional sight on cardiac failure: uncovered from structural to molecular level.

Authors:  Vijay Urmaliya; Gustavo Franchelli
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

2.  Pharmacy Support of a Pediatric Patient Receiving Milrinone at Home.

Authors:  Ariel Xue; Deonne Dersch-Mills; Clara Tsang; Steven C Greenway
Journal:  Can J Hosp Pharm       Date:  2016-10-31

Review 3.  Heart failure in single right ventricle congenital heart disease: physiological and molecular considerations.

Authors:  Anastacia M Garcia; Jonathan-Thomas Beatty; Stephanie J Nakano
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-02-28       Impact factor: 4.733

4.  Outcomes in Patients with Persistent Ventricular Dysfunction After Stage I Palliation for Hypoplastic Left Heart Syndrome.

Authors:  Emilie Jean-St-Michel; Devin Chetan; Steven M Schwartz; Glen S Van Arsdell; Alejandro A Floh; Osami Honjo; Jennifer Conway
Journal:  Pediatr Cardiol       Date:  2015-09-22       Impact factor: 1.655

5.  Age-related differences in phosphodiesterase activity and effects of chronic phosphodiesterase inhibition in idiopathic dilated cardiomyopathy.

Authors:  Stephanie J Nakano; Shelley D Miyamoto; Matthew Movsesian; Penny Nelson; Brian L Stauffer; Carmen C Sucharov
Journal:  Circ Heart Fail       Date:  2014-10-02       Impact factor: 8.790

6.  miRNA expression in pediatric failing human heart.

Authors:  Brian L Stauffer; Gloria Russell; Karin Nunley; Shelley D Miyamoto; Carmen C Sucharov
Journal:  J Mol Cell Cardiol       Date:  2013-01-17       Impact factor: 5.000

7.  Myocardial Response to Milrinone in Single Right Ventricle Heart Disease.

Authors:  Stephanie J Nakano; Penny Nelson; Carmen C Sucharov; Shelley D Miyamoto
Journal:  J Pediatr       Date:  2016-05-12       Impact factor: 4.406

8.  Pharmaceutical management of decompensated heart failure syndrome in children: current state of the art and a new approach.

Authors:  Avihu Z Gazit; Phineas P Oren
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-10

9.  Ambulatory Intravenous Inotropic Support and or Levosimendan in Pediatric and Congenital Heart Failure: Safety, Survival, Improvement, or Transplantation.

Authors:  Sotiria C Apostolopoulou; George A Vagenakis; Alexandros Tsoutsinos; Felicia Kakava; Spyridon Rammos
Journal:  Pediatr Cardiol       Date:  2018-05-18       Impact factor: 1.655

10.  Cardiac Adenylyl Cyclase and Phosphodiesterase Expression Profiles Vary by Age, Disease, and Chronic Phosphodiesterase Inhibitor Treatment.

Authors:  Stephanie J Nakano; Juliana Sucharov; Robert van Dusen; Mackenzie Cecil; Karin Nunley; Sean Wickers; Anis Karimpur-Fard; Brian L Stauffer; Shelley D Miyamoto; Carmen C Sucharov
Journal:  J Card Fail       Date:  2016-07-15       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.